{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T03:52:36Z","timestamp":1786420356821,"version":"build-2736575974"},"reference-count":41,"publisher":"Wiley","issue":"21","license":[{"start":{"date-parts":[[2013,8,6]],"date-time":"2013-08-06T00:00:00Z","timestamp":1375747200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2013,11]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Rituximab combined with chemotherapy has improved the survival of previously untreated patients with follicular lymphoma (FL). Nevertheless, many patients neither want nor can tolerate chemotherapy, leading to interest in biological approaches. Epratuzumab is a humanized anti\u2010CD22 monoclonal antibody with efficacy in relapsed FL. Because both rituximab and epratuzumab have single\u2010agent activity in FL, the antibody combination was evaluated as initial treatment of patients with FL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>\n                      Fifty\u2010nine untreated patients with FL received epratuzumab 360 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      with rituximab 375 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      weekly for 4 induction doses. This combination was continued as extended induction in weeks 12, 20, 28, and 36. Response assessed by computed tomography was correlated with clinical risk factors, [\n                      <jats:sup>18<\/jats:sup>\n                      F]fluorodeoxyglucose positron emission tomography findings at week 3, Fc\u03b3 polymorphisms, immunohistochemical markers, and statin use.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Therapy was well\u2010tolerated, with toxicities similar to expected with rituximab monotherapy. Fifty\u2010two (88.2%) evaluable patients responded, including 25 complete responses (42.4%) and 27 partial responses (45.8%). At 3 years follow\u2010up, 60% of patients remain in remission. Follicular Lymphoma International Prognostic Index (FLIPI) risk strongly predicted progression\u2010free survival (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.022).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>The high response rate and prolonged time to progression observed with this antibody combination are comparable to those observed after standard chemoimmunotherapies and further support the development of biologic, nonchemotherapeutic approaches for these patients. Cancer 2013;119:3797\u20133804. \u00a9 2013 American Cancer Society.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.28299","type":"journal-article","created":{"date-parts":[[2013,8,6]],"date-time":"2013-08-06T16:41:49Z","timestamp":1375807309000},"page":"3797-3804","source":"Crossref","is-referenced-by-count":51,"title":["A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701"],"prefix":"10.1002","volume":"119","author":[{"given":"Barbara W.","family":"Grant","sequence":"first","affiliation":[{"name":"Division of Hematology\u2010Oncology University of Vermont Medical Center Burlington Vermont"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sin\u2010Ho","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics Duke University Durham North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Alliance Statistical and Data Center Duke University Medical Center Durham North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lale","family":"Kostakoglu","sequence":"additional","affiliation":[{"name":"Department of Radiology Mt. Sinai Medical Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Hsi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology Cleveland Clinic Foundation Cleveland Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[{"name":"Ohio State University Cancer Center Columbus Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Jones","sequence":"additional","affiliation":[{"name":"Ohio State University Cancer Center Columbus Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Leonard","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2010Oncology Weill\u2010Cornell Medical College New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Eric","family":"Martin","sequence":"additional","affiliation":[{"name":"Christiana Care Health Services, Inc. CCOP Wilmington Delaware"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce D.","family":"Cheson","sequence":"additional","affiliation":[{"name":"Divison of Hematology\u2010Oncology Georgetown University Hospital Lombardi Comprehensive Cancer Center Washington DC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,8,6]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.5376"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.4618"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3411"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr620"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3179"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.05.6291"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-336990"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.01.082"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23890"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.018"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm114"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190903040048"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.754"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10682"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp460"},{"key":"e_1_2_7_21_1","first-page":"224A","article-title":"The architecural pattern of FOXP3+ T cells is an important predictor of survival in patients with follicular lymphoma","volume":"19","author":"Farinha P","year":"2006","journal-title":"Med Pathol."},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701665954"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1653"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/00401706.1983.10487819"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/10543400600825645"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.4245"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.4786"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.8508"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.30.18_suppl.3"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-1759(01)00338-6"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1309\/KPXNVR7X4AMENBBE"},{"issue":"10","key":"e_1_2_7_32_1","first-page":"3982S","article-title":"Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties","volume":"9","author":"Carnahan J","year":"2003","journal-title":"Clin Cancer Res."},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2006.05.007"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041869"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.8298"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-018218"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1565"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.1693"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.050419"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.0736"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701422059"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2007.n.005"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.28299","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.28299","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T16:50:36Z","timestamp":1760287836000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.28299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,6]]},"references-count":41,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["10.1002\/cncr.28299"],"URL":"https:\/\/doi.org\/10.1002\/cncr.28299","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718061028.793483604","asserted-by":"object"}]},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,6]]}}}